CNS Pharmaceuticals (NASDAQ:CNSP) Posts Quarterly Earnings Results, Beats Estimates By $1.52 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) posted its quarterly earnings data on Thursday. The company reported ($7.30) earnings per share for the quarter, topping the consensus estimate of ($8.82) by $1.52, FiscalAI reports.

CNS Pharmaceuticals Trading Down 1.2%

CNS Pharmaceuticals stock traded down $0.06 during midday trading on Friday, reaching $4.95. The stock had a trading volume of 32,195 shares, compared to its average volume of 4,339,569. CNS Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $16.56. The company has a market capitalization of $4.01 million, a P/E ratio of -0.17 and a beta of 2.62. The company has a fifty day moving average price of $3.17 and a two-hundred day moving average price of $4.92.

Institutional Trading of CNS Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. Ikarian Capital LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter valued at about $241,000. Finally, Boothbay Fund Management LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter valued at about $71,000. 14.02% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.